Drugs / MK0686
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00282763 | Dec 2005 → Aug 2006 | postherpetic neuralgia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00296569 | Sep 2005 → May 2006 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00533403 | Jul → Nov 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0686 | “This study is being conducted to assess the safety and tolerability of MK-0686 and to evaluate its efficacy in the treatment of osteoarthritis of the hip or knee in men and women.” NCT00296569 ↗ |
| Action | Inhibit | “Bradykinin B1 receptor antagonist” CHEMBL232943 ↗ |
| Modality | Small molecule | — CHEMBL232943 ↗ |
| Target | BDKRB1 | “Bradykinin B1 receptor antagonist” CHEMBL232943 ↗ |